Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 75

Results For "NAL"

5530 News Found

Crosslay Remedies acquires land adjacent to Max Super Speciality Hospital, Vaishali
News | May 20, 2025

Crosslay Remedies acquires land adjacent to Max Super Speciality Hospital, Vaishali

CRL shall invest another Rs. 200 crore for creation of additional beds


IICP and Indegene partner to enable more inclusive society
News | May 20, 2025

IICP and Indegene partner to enable more inclusive society

IICP is a registered charitable society working in the disability sector since 1974


Zydus Wellness records a growth of 30% in net profit in FY25
News | May 20, 2025

Zydus Wellness records a growth of 30% in net profit in FY25

EBITDA for the period rose by 23.2% to Rs. 3,797 million


Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr
News | May 18, 2025

Hikal posts Q4 FY25 consolidated PAT at Rs. 50 Cr

In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis


Briefs: Dr. Reddy's Laboratories, Relonchem,  Shilpa Pharma Lifesciences and Shanmuga Hospital
News | May 18, 2025

Briefs: Dr. Reddy's Laboratories, Relonchem, Shilpa Pharma Lifesciences and Shanmuga Hospital

Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA


Remedium Lifecare secures Rs. 182.7 crore export deal
News | May 16, 2025

Remedium Lifecare secures Rs. 182.7 crore export deal

The CDMO upgrade represents a transformational step for Remedium Lifecare


Shelter Pharma launches three new products
News | May 16, 2025

Shelter Pharma launches three new products

Shelter Pharma Limited is set to capitalize on the growing demand for natural health products in India


GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr
News | May 14, 2025

GlaxoSmithKline Pharmaceuticals posts FY25 PAT at Rs. 915 Cr

The Board of Directors of the company recommends a final dividend of Rs. 42 per equity share for the 12 months period ended March 31, 2025